Figure 3个  Table 3
    • Characteristic Total
      n = 27
      EN group
      n = 15
      LN group
      n = 12
      P value
      Age, median (IQR)—y 64.0 (57.0–72.0) 63.0 (57.0–72.0) 65.0 (56.2–78.0) 0.581
      Male sex—no. (%) 15 (55.5) 6 (40) 9 (75) 0.121
      Coexisting chronic disease—no. (%)
        Hypertension 12 (44.4) 6 (40) 6 (50) 0.707
        Coronary artery disease 2 (7.4) 1 (6.6) 1 (8.3) 1.000
        Diabetes 2 (7.4) 1 (6.6) 1 (8.3) 1.000
        Malignant tumor 3 (11.1) 2 (13.3) 1 (8.3) 1.000
        Neurological disorders 6 (22.2) 3 (20) 3 (25) 1.000
        Chronic kidney disease 1 (3.7) 0 1 (8.3)
        HIV/AIDS 2 (7.4) 0 2 (16.6)
        Chronic liver disease 2 (7.4) 0 1 (8.3)
      Laboratory tests before transfusion
        White-cell count, median (IQR)—(× 10−9/L) 5.37 (4.81–7.99) 6.49 (4.81–7.99) 4.16(3.31–7.47) 0.075
        Neutrophil count, median (IQR)—(× 10−9/L) 3.57 (2.58–5.58) 4.25 (2.94–5.70) 2.83(1.91–4.26) 0.083
        Lymphocyte count, median (IQR)—(× 10−9/L) 1.24 (0.62–1.85) 1.44 (0.46–1.85) 1.07 (0.64–1.33) 0.614
        Platelet count, median (IQR)—(× 10−9/L) 175 (137–194) 185 (163–219) 148 (78–183) 0.054
        Hematocrit, median (IQR)—(%) 33.4 (28.4–38.4) 33.4 (26.4–40.1) 34.1 (28.7–38.3) 0.943
        Serum creatinine, median (IQR)—(μmol/L) 69.1 (57.4–75.0) 66.0 (56.0–75.0) 70.5 (59.0–112.0) 0.683
      Total bilirubin, median (IQR)—(μmol/L) 11.4 (8.6–18.0) 11.9 (9.4–18.0) 10.8(8.1–20.0) 0.648
        Alanine aminotransferase, median (IQR)— (U/L) 17.0 (10.0-28.0) 24.0 (13.0–33.0) 13.0 (8.5–26.0) 0.103
        Aspartate aminotransferase, median (IQR)—(U/L) 26.0 (20.0–42.0.0) 27.0 (21.0–60.0) 24.5 (15.5–34.5) 0.516
        High-sensitivity C-reactive protein, median (IQR)—(mg/L) 3.1 (0.8–37.8) 3.1 (0.8–38.1) 3.9 (0.7–42.8) 0.733

      Table 1.  Demographic and clinical characteristics of patient before CP therapy.

    • Characteristic Total
      n = 27
      EN group
      n = 15
      LN group
      n = 12
      P value
      Interval between symptom onset and transfusion, median (IQR)—d 45.0 (35.0–49.0) 40.0 (26.0–47.0) 45.5 (41.2–57.0) 0.075
      Interval between symptom onset and last positive test before CP therapy, median (IQR)—d 44.0 (30.0–47.0) 39.0 (24.0–45.0) 44.5 (38.2–54.7) 0.126
      Body temperature, median (IQR)—℃ 36.9 (36.6–37.0) 36.8 (36.5–37.2) 36.9 (36.7–37.0) 0.516
      Fever—no. (%) 6 (22.2) 4 (26.6) 2 (16.6) 0.662
      Oxygen therapy—no. (%)
        No oxygen treatment 19 (70.3) 10 (66.6) 9 (75.0) 0.696
        Nasal catheter oxygen therapy 3 (11.1) 3 (20) 0 (0)
        Mechanical ventilation 5 (18.5) 2 (13.3) 3 (25.0) 1.000
        Extracorporeal membrane oxygenation 1 (3.7) 1 (6.6) 0 (0)
        Fraction of inspiration O2 (n = 26), median (IQR)—% 21.0 (21.0–33.0) 21.0 (21.0–33.0) 21.0 (21.0–35.2) 0.809
        Respiratory rate > 24 times/min—no. (%) 5 (18.5) 3 (20) 2 (16.6) 1.000
        Peripheral oxygen saturation, median (IQR)—% 98.0 (97.0–99.0) 97.0 (97.0–99.0) 97.0 (97.0–98.5) 0.905
        Vasopressors—no. (%) 4 (14.8) 1 (6.6) 3 (25.0) 0.294
      Anti-virus therapy—no. (%)
        Ribavirin 4 (14.8) 2 (13.3) 2 (16.6) 1.000
        Lopinavir 8 (29.6) 3 (20.0) 5 (41.6) 0.398
        Favipiravir 2 (7.4) 2 (13.3) 0 (0)
        Definite or suspected coinfection—no. (%) 6 (22.2) 3 (20.0) 3 (25.0) 0.433
        Broad-spectrum antibiotic therapy—no. (%) 15 (55.5) 8 (53.3) 7 (58.3) 1.000
        Corticoid therapy—no. (%) 5 (18.5) 3 (20) 2 (16.6) 1.000
        Immunoglobulin therapy—no. (%) 6 (22.2) 4 (26.6) 2 (16.6) 0.662

      Table 2.  Patients' status and treatments received before CP therapy.

    • Characteristic Total
      n = 27
      EN group
      n = 15
      LN group
      n = 12
      P value
      Total volume dose of CP, median (IQR)—mL 400 (200–600) 400 (200–400) 400 (400–800) 0.861
      Transfusion-related adverse reactions—no. (%) 0 (0) 0 (0) 0 (0)
      Interval between first transfusion and discharge, median (IQR)—d 11.0 (6.0–25.0) 7.0 (4.0–11.0) 24.0 (14.7–28.7)
      Pulmonary imaging improvement 15/20 7/8 8/12 0.603
      Length of hospital stay, median (IQR)—d 43.0 (24.0–54.0) 37.0 (19.0–50.0) 52.0 (35.0–63.7)
      Mortality of 60 days—no. (%) 3 (11.1) 0 (0) 3 (25)

      Table 3.  Patients' status after transfusion and outcome after CP therapy.